Antiva Biosciences Reports Promising Results from ABI-2280 Study for Cervical HPV Treatment
Antiva Biosciences has announced positive results from its Phase 1b/2 clinical trial of ABI-2280, a topical treatment for high-risk cervical HPV infections. The study, presented at the Society of Gynecologic Oncology Annual Meeting, showed that ABI-2280 achieved its primary and secondary endpoints, with significant improvements in HPV negativity rates at both 12 and 24 weeks compared to placebo. The treatment was well tolerated, with mild to moderate adverse events localized to the treatment area. The trial involved 139 women aged 25 to 55 with persistent HPV infections, demonstrating a 30% improvement in HPV negativity over placebo. 
